Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 128

1.

Should Transplantation Still Be Considered for Ph1-Negative Myeloproliferative Neoplasms in Transformation?

Ruggiu M, Cassinat B, Kiladjian JJ, Raffoux E, Giraudier S, Robin M, Itzykson R, Clappier E, Michonneau D, de Fontbrune FS, de Latour RP, Ades L, Socié G.

Biol Blood Marrow Transplant. 2020 Feb 28. pii: S1083-8791(20)30105-1. doi: 10.1016/j.bbmt.2020.02.019. [Epub ahead of print]

2.

Correction: Despite mutation acquisition in hematopoietic stem cells, JMML-propagating cells are not always restricted to this compartment.

Caye A, Rouault-Pierre K, Strullu M, Lainey E, Abarrategi A, Fenneteau O, Arfeuille C, Osman J, Cassinat B, Pereira S, Anjos-Afonso F, Currie E, Ariza-McNaughton L, Barlogis V, Dalle JH, Baruchel A, Chomienne C, Cavé H, Bonnet D.

Leukemia. 2020 Jan 31. doi: 10.1038/s41375-020-0720-5. [Epub ahead of print]

PMID:
32005921
3.

MPL mutations in essential thrombocythemia uncover a common path of activation with eltrombopag dependent on W491.

Levy G, Carillo S, Papoular B, Cassinat B, Zini JM, Leroy E, Varghese LN, Chachoua I, Defour JP, Smith SO, Constantinescu SN.

Blood. 2020 Mar 19;135(12):948-953. doi: 10.1182/blood.2019003240.

PMID:
31978223
4.

Rare and private spliceosomal gene mutations drive partial, complete, and dual phenocopies of hotspot alterations.

Pangallo J, Kiladjian JJ, Cassinat B, Renneville A, Taylor J, Polaski JT, North K, Abdel-Wahab O, Bradley RK.

Blood. 2020 Mar 26;135(13):1032-1043. doi: 10.1182/blood.2019002894.

5.

Despite mutation acquisition in hematopoietic stem cells, JMML-propagating cells are not always restricted to this compartment.

Caye A, Rouault-Pierre K, Strullu M, Lainey E, Abarrategi A, Fenneteau O, Arfeuille C, Osman J, Cassinat B, Pereira S, Anjos-Afonso F, Currie E, Ariza-McNaughton L, Barlogis V, Dalle JH, Baruchel A, Chomienne C, Cavé H, Bonnet D.

Leukemia. 2019 Nov 27. doi: 10.1038/s41375-019-0662-y. [Epub ahead of print] Erratum in: Leukemia. 2020 Jan 31;:.

PMID:
31776464
6.

Synergistic effects of PRIMA-1Met (APR-246) and Azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia.

Maslah N, Salomao N, Drevon L, Verger E, Partouche N, Ly P, Aubin P, Naoui N, Schlageter MH, Bally C, Miekoutima E, Rahmé R, Lehmann-Che J, Ades L, Fenaux P, Cassinat B, Giraudier S.

Haematologica. 2019 Sep 5. pii: haematol.2019.218453. doi: 10.3324/haematol.2019.218453. [Epub ahead of print]

7.

Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL mutation.

Mannina D, Gagelmann N, Badbaran A, Ditschkowski M, Bogdanov R, Robin M, Cassinat B, Heuser M, Shahswar R, Thol F, Beelen D, Kröger N.

Eur J Haematol. 2019 Dec;103(6):552-557. doi: 10.1111/ejh.13318. Epub 2019 Sep 16.

PMID:
31446640
8.

Masked polycythemia vera: analysis of a single center cohort of 2480 red cell masses.

Maslah N, Soret J, Dosquet C, Vercellino L, Belkhodja C, Schlageter MH, Cassinat B, Kiladjian JJ, Chomienne C, Giraudier S.

Haematologica. 2020 Mar;105(3):e95-e97. doi: 10.3324/haematol.2018.215582. Epub 2019 Aug 14. No abstract available.

9.

How much does 2016 WHO classification of myeloproliferative neoplasms affect the clinic?

Cassinat B, Giraudier S, Kiladjian JJ.

Expert Rev Hematol. 2019 Jul;12(7):473-476. doi: 10.1080/17474086.2019.1623019. Epub 2019 Jun 4. No abstract available.

PMID:
31161817
10.

A Constitutional Activating MET Mutation Makes the Genetic Link between Malignancies and Chronic Inflammatory Diseases.

El Bouchtaoui M, Do Cruzeiro M, Leboeuf C, Loisel-Ferreira I, Fedronie C, Ferreira C, Ait El Far R, Ziol M, Espié M, Falgarone G, Cassinat B, Kiladjian JJ, Feugeas JP, Janin A, Bousquet G.

Clin Cancer Res. 2019 Jul 15;25(14):4504-4515. doi: 10.1158/1078-0432.CCR-18-3261. Epub 2019 Apr 19.

PMID:
31004003
11.

When hemolysis masks polycythemia vera.

Derrieux C, Jeandel R, Martin A, Dosquet C, Cassinat B, Fouillard L.

Clin Case Rep. 2019 Jan 28;7(3):438-441. doi: 10.1002/ccr3.1776. eCollection 2019 Mar.

12.

Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation.

Gagelmann N, Ditschkowski M, Bogdanov R, Bredin S, Robin M, Cassinat B, Shahswar R, Thol F, Heuser M, Socié G, Beelen D, Triviai I, Badbaran A, Kröger N.

Blood. 2019 May 16;133(20):2233-2242. doi: 10.1182/blood-2018-12-890889. Epub 2019 Feb 13.

PMID:
30760453
13.

Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations.

Jutzi JS, Basu T, Pellmann M, Kaiser S, Steinemann D, Sanders MA, Hinai ASA, Zeilemaker A, Bojtine Kovacs S, Koellerer C, Ostendorp J, Aumann K, Wang W, Raffoux E, Cassinat B, Bullinger L, Schlegelberger B, Valk PJM, Pahl HL.

Blood. 2019 Apr 18;133(16):1766-1777. doi: 10.1182/blood-2018-09-875047. Epub 2019 Feb 12.

14.

International external quality assurance of JAK2 V617F quantification.

Asp J, Skov V, Bellosillo B, Kristensen T, Lippert E, Dicker F, Schwarz J, Wojtaszewska M, Palmqvist L, Akiki S, Aggerholm A, Tolstrup Andersen M, Girodon F, Kjær L, Oppliger Leibundgut E, Pancrazzi A, Vorland M, Andrikovics H, Kralovics R, Cassinat B, Coucelo M, Eftimov A, Haslam K, Kusec R, Link-Lenczowska D, Lodé L, Matiakowska K, Naguib D, Navaglia F, Novotny GW, Percy MJ, Sudarikov A, Hermouet S, Pallisgaard N.

Ann Hematol. 2019 May;98(5):1111-1118. doi: 10.1007/s00277-018-3570-8. Epub 2018 Dec 8.

15.

Exome analysis of treatment-related AML after APL suggests secondary evolution.

Wang T, Jacoby MA, Duncavage EJ, Miller CA, Heath S, Rahme R, Fenaux P, Ades L, Renneville A, Cassinat B, Takeshita A, Asou N, Miyazaki Y, Kiyoi H, Ravandi F, Westervelt P, Wartman LD, Welch JS.

Br J Haematol. 2019 Jun;185(5):984-987. doi: 10.1111/bjh.15681. Epub 2018 Nov 22. No abstract available.

PMID:
30467844
16.

Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo.

Verger E, Soret-Dulphy J, Maslah N, Roy L, Rey J, Ghrieb Z, Kralovics R, Gisslinger H, Grohmann-Izay B, Klade C, Chomienne C, Giraudier S, Cassinat B, Kiladjian JJ.

Blood Cancer J. 2018 Oct 4;8(10):94. doi: 10.1038/s41408-018-0133-0.

17.

Next-generation sequencing for JAK2 mutation testing: advantages and pitfalls.

Maslah N, Verger E, Schlageter MH, Miclea JM, Kiladjian JJ, Giraudier S, Chomienne C, Cassinat B.

Ann Hematol. 2019 Jan;98(1):111-118. doi: 10.1007/s00277-018-3499-y. Epub 2018 Sep 26.

PMID:
30259120
18.

Endothelial Cells Harbouring the JAK2V617F Mutation Display Pro-Adherent and Pro-Thrombotic Features.

Guadall A, Lesteven E, Letort G, Awan Toor S, Delord M, Pognant D, Brusson M, Verger E, Maslah N, Giraudier S, Larghero J, Vanneaux V, Chomienne C, El Nemer W, Cassinat B, Kiladjian JJ.

Thromb Haemost. 2018 Sep;118(9):1586-1599. doi: 10.1055/s-0038-1667015. Epub 2018 Aug 13.

PMID:
30103245
19.

Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia.

Lehmann-Che J, Bally C, Letouzé E, Berthier C, Yuan H, Jollivet F, Ades L, Cassinat B, Hirsch P, Pigneux A, Mozziconacci MJ, Kogan S, Fenaux P, de Thé H.

Nat Commun. 2018 May 24;9(1):2047. doi: 10.1038/s41467-018-04384-5.

20.

Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia.

Renneville A, Attias P, Thomas X, Bally C, Hayette S, Farhat H, Eclache V, Marceau-Renaut A, Cassinat B, Feuillard J, Terré C, Delabesse E, Park S, Lejeune J, Chevret S, Adès L, Preudhomme C, Fenaux P.

Leukemia. 2018 Sep;32(9):2066-2069. doi: 10.1038/s41375-018-0137-6. Epub 2018 Apr 18. No abstract available.

PMID:
29740159
21.

New chimeric RNAs in acute myeloid leukemia.

Rufflé F, Audoux J, Boureux A, Beaumeunier S, Gaillard JB, Bou Samra E, Megarbane A, Cassinat B, Chomienne C, Alves R, Riquier S, Gilbert N, Lemaitre JM, Bacq-Daian D, Bougé AL, Philippe N, Commes T.

Version 2. F1000Res. 2017 Aug 2 [revised 2017 Jan 1];6. pii: ISCB Comm J-1302. doi: 10.12688/f1000research.11352.2. eCollection 2017.

22.

Impact of hydroxycarbamide and interferon-α on red cell adhesion and membrane protein expression in polycythemia vera.

Brusson M, De Grandis M, Cochet S, Bigot S, Marin M, Leduc M, Guillonneau F, Mayeux P, Peyrard T, Chomienne C, Le Van Kim C, Cassinat B, Kiladjian JJ, El Nemer W.

Haematologica. 2018 Jun;103(6):972-981. doi: 10.3324/haematol.2017.182303. Epub 2018 Mar 29.

23.

Clonal Hematopoiesis and Atherosclerosis.

Cassinat B, Harrison C, Kiladjian JJ.

N Engl J Med. 2017 Oct 5;377(14):1400-1. doi: 10.1056/NEJMc1710381. No abstract available.

PMID:
28980792
24.

Correction for Cassinat et al., "New Role for Granulocyte Colony-Stimulating Factor-Induced Extracellular Signal-Regulated Kinase 1/2 in Histone Modification and Retinoic Acid Receptor α Recruitment to Gene Promoters: Relevance to Acute Promyelocytic Leukemia Cell Differentiation".

Cassinat B, Zassadowski F, Ferry C, Llopis L, Bruck N, Lainey E, Duong V, Cras A, Despouy G, Chourbagi O, Beinse G, Fenaux P, Rochette Egly C, Chomienne C.

Mol Cell Biol. 2017 Jun 29;37(14). pii: e00222-17. doi: 10.1128/MCB.00222-17. Print 2017 Jul 15. No abstract available.

25.

The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders.

Maslah N, Cassinat B, Verger E, Kiladjian JJ, Velazquez L.

Leukemia. 2017 Aug;31(8):1661-1670. doi: 10.1038/leu.2017.139. Epub 2017 May 9. Review.

PMID:
28484264
26.

Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study.

Poisson J, Plessier A, Kiladjian JJ, Turon F, Cassinat B, Andreoli A, De Raucourt E, Goria O, Zekrini K, Bureau C, Lorre F, Cervantes F, Colomer D, Durand F, Garcia-Pagan JC, Casadevall N, Valla DC, Rautou PE, Marzac C; French national network for vascular liver diseases.

J Hepatol. 2017 Sep;67(3):501-507. doi: 10.1016/j.jhep.2017.04.021. Epub 2017 May 5.

PMID:
28483676
27.

Enhanced calreticulin expression in red cells of polycythemia vera patients harboring the JAK2V617F mutation.

Brusson M, Cochet S, Leduc M, Guillonneau F, Mayeux P, Peyrard T, Chomienne C, Le Van Kim C, Cassinat B, Kiladjian JJ, El Nemer W.

Haematologica. 2017 Jul;102(7):e241-e244. doi: 10.3324/haematol.2016.161604. Epub 2017 Apr 6. No abstract available.

28.

Assessing Bone Marrow Activity in Patients with Myelofibrosis: Results of a Pilot Study of 18F-FLT PET.

Vercellino L, Ouvrier MJ, Barré E, Cassinat B, de Beco V, Dosquet C, Chevret S, Meignin V, Chomienne C, Toubert ME, Merlet P, Kiladjian JJ.

J Nucl Med. 2017 Oct;58(10):1603-1608. doi: 10.2967/jnumed.116.188508. Epub 2017 Mar 30.

29.

Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy.

Felix J, Cassinat B, Porcher R, Schlageter MH, Maubec E, Pages C, Baroudjian B, Homyrda L, Boukouaci W, Tamouza R, Bagot M, Caignard A, Toubert A, Lebbé C, Moins-Teisserenc H.

Int Immunopharmacol. 2016 Nov;40:466-473. doi: 10.1016/j.intimp.2016.09.030. Epub 2016 Oct 8.

PMID:
27728898
30.

Chemotherapy for post-myelofibrosis acute myeloid leukemia: eradication of the leukemic clone but not the MPN clone.

Verger E, Rattarittamrong E, Letort G, Raffoux E, Cassinat B, Kiladjian JJ.

Leuk Lymphoma. 2017 Mar;58(3):749-751. doi: 10.1080/10428194.2016.1213833. Epub 2016 Aug 11. No abstract available.

PMID:
27562925
31.

Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis.

Robin M, Porcher R, Wolschke C, Sicre de Fontbrune F, Alchalby H, Christopeit M, Cassinat B, Zabelina T, Peffault de Latour R, Ayuk F, Socié G, Kröger N.

Biol Blood Marrow Transplant. 2016 Jul;22(7):1206-1211. doi: 10.1016/j.bbmt.2016.02.019. Epub 2016 Mar 10.

32.

Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone.

Kiladjian JJ, Giraudier S, Cassinat B.

Leukemia. 2016 Apr;30(4):776-81. doi: 10.1038/leu.2015.326. Epub 2015 Nov 25. Review.

PMID:
26601783
33.

Quantification of the Mutant CALR Allelic Burden by Digital PCR: Application to Minimal Residual Disease Evaluation after Bone Marrow Transplantation.

Mansier O, Migeon M, Saint-Lézer A, James C, Verger E, Robin M, Socié G, Bidet A, Mahon FX, Cassinat B, Lippert E.

J Mol Diagn. 2016 Jan;18(1):68-74. doi: 10.1016/j.jmoldx.2015.07.007. Epub 2015 Nov 18.

34.

Unexplained thrombocytosis: association of Baltimore polymorphism with germline MPL nonsense mutation.

Verger E, Teillet F, Conejero C, Letort G, Chomienne C, Giraudier S, Cassinat B.

Br J Haematol. 2016 Oct;175(1):167-9. doi: 10.1111/bjh.13840. Epub 2015 Nov 16. No abstract available.

PMID:
26568271
35.

Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations.

Verger E, Cassinat B, Chauveau A, Dosquet C, Giraudier S, Schlageter MH, Ianotto JC, Yassin MA, Al-Dewik N, Carillo S, Legouffe E, Ugo V, Chomienne C, Kiladjian JJ.

Blood. 2015 Dec 10;126(24):2585-91. doi: 10.1182/blood-2015-07-659060. Epub 2015 Oct 20.

PMID:
26486786
36.

Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network.

Caye A, Strullu M, Guidez F, Cassinat B, Gazal S, Fenneteau O, Lainey E, Nouri K, Nakhaei-Rad S, Dvorsky R, Lachenaud J, Pereira S, Vivent J, Verger E, Vidaud D, Galambrun C, Picard C, Petit A, Contet A, Poirée M, Sirvent N, Méchinaud F, Adjaoud D, Paillard C, Nelken B, Reguerre Y, Bertrand Y, Häussinger D, Dalle JH, Ahmadian MR, Baruchel A, Chomienne C, Cavé H.

Nat Genet. 2015 Nov;47(11):1334-40. doi: 10.1038/ng.3420. Epub 2015 Oct 12.

PMID:
26457648
37.

Low incidence of CALR gene mutations in patients with cerebral venous thrombosis without overt chronic myeloproliferative neoplasm.

Verger E, Crassard I, Cassinat B, Bellucci S.

Thromb Res. 2015 Oct;136(4):839-40. doi: 10.1016/j.thromres.2015.07.026. Epub 2015 Jul 29. No abstract available.

PMID:
26281713
38.

Lithium chloride antileukemic activity in acute promyelocytic leukemia is GSK-3 and MEK/ERK dependent.

Zassadowski F, Pokorna K, Ferre N, Guidez F, Llopis L, Chourbagi O, Chopin M, Poupon J, Fenaux P, Ann Padua R, Pla M, Chomienne C, Cassinat B.

Leukemia. 2015 Dec;29(12):2277-84. doi: 10.1038/leu.2015.159. Epub 2015 Jun 25.

PMID:
26108692
39.

Yeast Assay Highlights the Intrinsic Genomic Instability of Human PML Intron 6 over Intron 3 and the Role of Replication Fork Proteins.

Chanet R, Kienda G, Heneman-Masurel A, Vernis L, Cassinat B, Guardiola P, Fenaux P, Chomienne C, Huang ME.

PLoS One. 2015 Jun 8;10(6):e0129222. doi: 10.1371/journal.pone.0129222. eCollection 2015.

40.

Lu/BCAM-mediated cell adhesion as biological marker of JAK2V617F activity in erythrocytes of polycythemia vera patients.

De Grandis M, Cassinat B, Kiladjian JJ, Chomienne C, El Nemer W.

Am J Hematol. 2015 Jul;90(7):E137-8. doi: 10.1002/ajh.24023. Epub 2015 May 28. No abstract available.

41.

Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet.

Lengfelder E, Lo-Coco F, Ades L, Montesinos P, Grimwade D, Kishore B, Ramadan SM, Pagoni M, Breccia M, Huerta AJ, Nloga AM, González-Sanmiguel JD, Schmidt A, Lambert JF, Lehmann S, Di Bona E, Cassinat B, Hofmann WK, Görlich D, Sauerland MC, Fenaux P, Sanz M; European LeukemiaNet.

Leukemia. 2015 May;29(5):1084-91. doi: 10.1038/leu.2015.12. Epub 2015 Jan 28.

PMID:
25627637
42.

Juvenile myelomonocytic leukaemia and Noonan syndrome.

Strullu M, Caye A, Lachenaud J, Cassinat B, Gazal S, Fenneteau O, Pouvreau N, Pereira S, Baumann C, Contet A, Sirvent N, Méchinaud F, Guellec I, Adjaoud D, Paillard C, Alberti C, Zenker M, Chomienne C, Bertrand Y, Baruchel A, Verloes A, Cavé H.

J Med Genet. 2014 Oct;51(10):689-97. doi: 10.1136/jmedgenet-2014-102611. Epub 2014 Aug 5.

PMID:
25097206
43.

Interferon alfa therapy in CALR-mutated essential thrombocythemia.

Cassinat B, Verger E, Kiladjian JJ.

N Engl J Med. 2014 Jul 10;371(2):188-9. doi: 10.1056/NEJMc1401255. No abstract available.

PMID:
25006741
44.

Association of a single-nucleotide polymorphism in the SH2B3 gene with JAK2V617F-positive myeloproliferative neoplasms.

Lesteven E, Picque M, Conejero Tonetti C, Giraudier S, Varin-Blank N, Velazquez L, Kiladjian JJ, Cassinat B, Baran-Marszak F.

Blood. 2014 Jan 30;123(5):794-6. doi: 10.1182/blood-2013-10-532622. No abstract available.

PMID:
24482502
45.

Management and treatment results in patients with acute promyelocytic leukaemia (APL) not enrolled in clinical trials.

Micol JB, Raffoux E, Boissel N, Lengliné E, Canet E, Daniel MT, Labarthe Ad, Maarek O, Cassinat B, Adès L, Baruchel A, Degos L, Azoulay E, Dombret H.

Eur J Cancer. 2014 Apr;50(6):1159-68. doi: 10.1016/j.ejca.2013.11.023. Epub 2014 Jan 15.

PMID:
24440088
46.

TET2 gene sequencing may be helpful for myeloproliferative neoplasm diagnosis.

Verger E, Andreoli A, Chomienne C, Kiladjian JJ, Cassinat B.

Br J Haematol. 2014 May;165(3):416-9. doi: 10.1111/bjh.12738. Epub 2014 Jan 16. No abstract available.

PMID:
24433485
47.

Use of the 46/1 haplotype to model JAK2(V617F) clonal architecture in PV patients: clonal evolution and impact of IFNα treatment.

Hasan S, Cassinat B, Droin N, Le Couedic JP, Favale F, Monte-Mor B, Lacout C, Fontenay M, Dosquet C, Chomienne C, Solary E, Villeval JL, Casadevall N, Kiladjian JJ, Vainchenker W, Plo I.

Leukemia. 2014 Feb;28(2):460-3. doi: 10.1038/leu.2013.303. Epub 2013 Oct 22. No abstract available.

PMID:
24150219
48.

Increased reactive oxygen species production and p47phox phosphorylation in neutrophils from myeloproliferative disorders patients with JAK2 (V617F) mutation.

Hurtado-Nedelec M, Csillag-Grange MJ, Boussetta T, Belambri SA, Fay M, Cassinat B, Gougerot-Pocidalo MA, Dang PM, El-Benna J.

Haematologica. 2013 Oct;98(10):1517-24. doi: 10.3324/haematol.2012.082560. Epub 2013 Aug 23.

49.

Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study.

Jovanovic JV, Ivey A, Vannucchi AM, Lippert E, Oppliger Leibundgut E, Cassinat B, Pallisgaard N, Maroc N, Hermouet S, Nickless G, Guglielmelli P, van der Reijden BA, Jansen JH, Alpermann T, Schnittger S, Bench A, Tobal K, Wilkins B, Cuthill K, McLornan D, Yeoman K, Akiki S, Bryon J, Jeffries S, Jones A, Percy MJ, Schwemmers S, Gruender A, Kelley TW, Reading S, Pancrazzi A, McMullin MF, Pahl HL, Cross NC, Harrison CN, Prchal JT, Chomienne C, Kiladjian JJ, Barbui T, Grimwade D.

Leukemia. 2013 Oct;27(10):2032-9. doi: 10.1038/leu.2013.219. Epub 2013 Jul 17.

50.

In hematopoietic cells with a germline mutation of CBL, loss of heterozygosity is not a signature of juvenile myelo-monocytic leukemia.

Strullu M, Caye A, Cassinat B, Fenneteau O, Touzot F, Blauwblomme T, Rodriguez R, Latour S, Petit A, Barlogis V, Galambrun C, Leblanc T, Baruchel A, Chomienne C, Cavé H.

Leukemia. 2013 Dec;27(12):2404-7. doi: 10.1038/leu.2013.203. Epub 2013 Jul 4. No abstract available.

PMID:
23823657

Supplemental Content

Loading ...
Support Center